The Multicenter Diltiazem Postinfarction Trial (MDPIT) reported no consistent diltiazem effect on new or worsened congestive heart failure (CHF) during 12-52 months' follow-up after acute myocardial infarction. This was puzzling in light of the observation that patients with findings suggesting left ventricular dysfunction (LVD) at baseline on diltiazem had more cardiac events (cardiac mortality or recurrent nonfatal infarction) than such patients on placebo. We hypothesized that diltiazem increased the frequency of late CHF as well as of cardiac events, but only in patients predisposed by LVD. Using the same characterizing variables as the primary MDPIT analysis, we found that patients with pulmonary congestion, anterolateral Q wave infarction, or reduced ejection fraction (EF) at baseline were more likely to have CHF during follow-up than those without these markers of LVD. CHF was particularly frequent in the patients with LVI) who were randomized to diltiazem. Among those with a baseline EF of less than 0.40, late CHF appeared in 12% (39/326) receiving placebo and 21% (61/297) receiving diltiazem (p=0.004). Life table analysis in patients with an EF of less than 0.40 confirmed more frequent late CHF in those taking diltiazem (p=0.0017). In addition, the diltiazem-associated rise in the frequency of late CHF was progressively greater with increasingly severe decrements in baseline EF. This diltiazem effect was absent in patients with pulmonary congestion at baseline but an EF of 0.40 or more, suggesting a unique association between diltiazem-related late CHF and systolic LVD. Diltiazemassociated enhancement of CHF in patients with an EF of less than 0.40 was evident among those who took concomitant ,B-blockers and among those who did not. We conclude that postinfarction patients with reduced EF are at particular risk for subsequent CHF when treated with diltiazem. This problem, along with the greater occurrence of cardiac events in patients with LVD, indicates a need for caution when giving diltiazem to patients with postinfarction LVD. (Circulation 1991;83:52-60) D iltiazem is effective in suppressing myocardial ischemia in patients with coronary artery disease.1-4 However, diltiazem and other calcium channel blockers can augment hemodynamic abnormalities in patients with congestive heart failure (CHF).5-9 These contrary actions would explain the findings of the Multicenter Diltiazem
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Methods

General Study Procedures
MDPIT was a randomized, double-blind, placebocontrolled trial of diltiazem in 2,466 postinfarction patients followed up for The primary end points for MDPIT were 1) first recurrent cardiac event (as defined above) and 2) cardiac mortality. Initial analysis related these end points to the assigned treatment and examined potential interactions between assigned treatment and 12 prespecified baseline variables.10 Bidirectional interaction was evident for three variables: in patients taking diltiazem, the presence of PC (p<0.01), ALQMI, or EF less than 0.40 at baseline was associated with an increased incidence of first recurrent cardiac events relative to those taking placebo (hazard ratio 1.13-1.41) and the absence of each variable was associated with a reduced incidence of these events (hazard ratio 0.73-0.77). In the present analysis these three baseline variables were related to the occurrence of new or worsened CHF during follow-up (termed "late CHF").
For the present analysis patients were judged to have late CHF based upon one or more reports of this problem during follow-up. All such reports were utilized regardless of whether the center investigator considered the adverse experience to be drug-re- April 16, 1988 . This data base differs slightly from the one released November 1, 1987, which was used in the primary article.10 The updated data base resulted from ongoing quality control procedures and the late receipt (after November 1, 1987) of a small amount of study data. Changes in the data base involved less than 0.15% of the baseline and follow-up data, and the changes were made without knowledge of trial medication assignment or end point events. Results of the analyses using the updated data base were only negligibly different from the findings reported in the primary article. Specifically, the hazard ratios for primary end points and the occurrence rates for CHF were unchanged from those initially reported when recalculated using data base version 2.0. The hazard ratios in subgroups defined by left ventricular dysfunction (PC, ALQMI or EF less than 0.40) were each changed by less than 4%.
Results
Effects of Baseline Variables on Late CHF
The primary MDPIT analysis showed that PC, ALQMI, or EF less than 0.40 at baseline was predictive of an increased frequency of cardiac death or nonfatal reinfarction during long-term follow-up of patients assigned to take placebo.10 The same was true for late CHF: placebo-treated patients with baseline PC had a 3.3-fold increase, those with ALQMI a 1.6-fold increase, and those with EF less than 0.40 a 2.8 -fold increase in the occurrence of late CHF relative to patients lacking the corresponding baseline abnormality (Table 1) . Thus, EF separated postinfarction patients into groups with high and low likelihoods of CHF during long-term follow-up. However, the routinely evaluated radiographic assessment of PC at baseline was also very effective in achieving this separation.
Diltiazem treatment had no influence on the occurrence of late CHF in any of the subsets with normal baseline variables (Table 1 ). In contrast, assignment to diltiazem appeared to increase the occurrence of late CHF in groups with PC, ALQMI, or EF less than 0.40. Although this was only a tendency for PC, the effect of diltiazem treatment was borderline significant (p=0.041) for ALQMI and highly significant (p=0.004) for EF less than 0.40. This effect of diltiazem did not bear an ordinal relation to the occurrence of late CHF in the absence of diltiazem: the group with the greatest diltiazem-related change (patients with EF less than 0.40) exhibited neither the highest nor the lowest occurrence of late CHF when its members received placebo.
To examine the interaction of EF, PC, and diltiazem, we separately assessed the occurrence of late CHF in patient subsets defined by baseline EF and PC as well as treatment status (Figure 1 of late CHF was also observed in diltiazem-treated patients with baseline EF less than 0.40 determined after the study drug was started. The homogeneity of diltiazem's influence provided justification for the pooling of data from patients with early and late determination of baseline EF.
Detailed Analyses of Baseline EF and Late CHF
The relation between baseline EF and late CHF was further explored by comparing placebo-and diltiazem-treated subsets within each of four EF categories (Figure 2 ). The occurrence of late CHF was low (3.9% overall) in patients with normal baseline EF (.0.45) and not different in subsets treated with placebo or diltiazem. Progressively more severe impairment of baseline EF was associated with progressively greater occurrence of late CHF. Although this increase was evident for both placebo-and diltiazem-treated subsets, patients receiving diltiazem had a more rapid rise. Thus, the more severe the reduction in baseline EF, the greater the increment in diltiazem-associated occurrence of late CHF relative to placebo. This was evident in the ratio of percentages with CHF in each treatment category (Figure 2 ). These ratios increased with declining baseline EF, reaching a maximum of 1.78 (i.e., a 78% greater occurrence of late CHF) associated with diltiazem treatment in the lowest EF category (<0.25).
The association between diltiazem treatment and increased occurrence of late CHF in patients with reduced EF was further substantiated by life table analysis of patients with EF less than 0.40 (Figure 3 ). Patients receiving placebo had a relatively high rate of CHF occurrence during the first 60 days after randomization, with a gradual shift to a lesser rate that remained stable for the balance of the study. Patients receiving diltiazem had an initial rate of CHF occurrence that was substantially greater than the initial rate for patients receiving placebo. The curves for placebo-and diltiazem-treated patients were roughly parallel for the remainder of the study, suggesting that later occurrence rates were similar in the two treatment subsets. The (Figure 4 ), an outcome that may reflect selection bias (fl-blockers were not randomly allocated) as well as a drug effect. Occurrence of late CHF was compared in placebo-and diltiazem-treated patients within groups defined by fl-blocker use and baseline EF (Figure 4) . Diltiazem treatment was associated with an increased frequency of late CHF in both patient groups having EF less than 0.40 -those not using fl-blockers (ratio of percentages with late CHF [diltiazem/placebo]= 1.80) as well as those using f8-blockers (ratio of percentages= 1.54). The connection with diltiazem was stronger and significant (p=0.008) in patients with EF less than 0.40 not using fl-blockers. In patients with EF less than 0.40 who used fl-blockers, the diltiazemassociated increase was not significant (p=0.22). Diltiazem treatment was not associated with an increased frequency of late CHF in patients with EF of 0.40 or more, independent of fl-blocker usage. Clinical Events in Patients With Late CHF New or worsened CHF during follow-up was reported as "a potentially serious cardiovascular complication" by the local center investigator in 157 of 177 instances (89%). Study medication was discontinued during 45% (80) of these episodes. Only 13 of the episodes (7%) occurred within 1 week of a cardiac event (recurrent nonfatal myocardial infarction or cardiac death). Of the patients experiencing new or worsened CHF, 69 (39%) eventually developed cardiac events and 52 (29%) had cardiac deaths. These rates are 3.4-fold and 2.5-fold greater, respectively, than corresponding rates for patients without CHF. Cardiac mortality occurred in 34 (35%) of 96 patients with late CHF assigned to diltiazem treatment and in 18 (22%) of 81 patients with late CHF assigned to placebo (p=0.055).
Pathophysiologic events at the time of death were not examined in the present analysis. In a recent evaluation of MDPIT data, Marcus et al14 stated, "There was no evidence that the ratio of arrhythmia to myocardial failure deaths varied for patients with pulmonary congestion compared to those without it, and this ratio did not vary significantly between treatment groups." Discussion The primary MDPIT analysis found no overall increase in the frequency of late CHF among postinfarction patients receiving diltiazem.10 The analysis also identified a diltiazem-related increment in the frequency of recurrent cardiac events in patients with early evidence of left ventricular dysfunction.10'11 These results were puzzling: diltiazem-induced exacerbation of impaired performance was suggested by the cardiac event data but not confirmed by the data regarding late CHF. The present, secondary analysis extends and clarifies the previous findings by showing that late CHF occurs more frequently in patients with the same markers of left ventricular dysfunction identified in the primary MDPIT analysis (Table 1) .
Results from the Beta-Blocker Heart Attack Trial (BHAT) generally support this association: a twofold to threefold increase in the frequency of late CHF was noted among patients with previous myocardial infarction, history of CHF before the index infarction, enlarged cardiothoracic ratio, use of digitalis, and other clinical indicators of left ventricular dysfunction.15
More importantly, the present analysis of MDPIT data demonstrates that patients with peri-infarction left ventricular dysfunction assigned to diltiazem more frequently have new or worsened CHF during follow-up than patients assigned to placebo. This appears particularly evident for patients with reduced EF. A highly significant diltiazem-associated increment in the frequency of late CHF is seen among patients with EF less than 0.40 (Table 1) . This is further supported by the progressive rise of the diltiazem-associated increment in occurrence of late CHF with greater reduction in EF (Figure 2 ) and by the consistently increased incidence of late CHF in diltiazem-treated individuals observed on life table analysis of patients with EF less than 0.40 (Figure 3) .
These results could reflect an imbalanced distribution of adverse characteristics in placebo-and diltiazem-treated subsets as well as diltiazem effects that promote late CHF. However, the blinded, randomized character of MDPIT drug assignment acted to balance clinical variables, supplemental pharmacologic management, and end point identification. The comparability of patients in placebo-and diltiazem-treated subsets is further substantiated by examination of relevant clinical parameters ( Figure 2 ). This increase is not seen in patients with PC and EF of 0.40 or more despite the frequent (11%) occurrence of late CHF. Diltiazem may cause particularly evident adverse effects in patients with systolic dysfunction (reduced EF). Such effects may be mitigated by favorable actions of calcium channel blockade in patients whose main difficulty is ischemia or diastolic dysfunction (PC with normal EF).
It is noteworthy that long-term diltiazem treatment appeared to increase the frequency of late CHF in postinfarction patients with left ventricular dysfunction, while a similar adverse drug action was not found in BHAT, a randomized study of proprano-101. 15 This may reflect differing effects of calcium channel blockers and /3-blockers on neuroendocrine activation.16 However, the MDPIT data demonstrated an unequivocal diltiazem-related increase in the frequency of late CHF only in patients with EF less than 0.40, a group not defined in BHAT. The MDPIT group identified by PC, a less precise measure of left ventricular dysfunction, showed a nonsignificant trend toward a diltiazem-related increase in the frequency of late CHF (Table 1 ). This finding is not very different from the BHAT results regarding propranolol in the postinfarction patients at higher risk for CHF.15 Mortality data more clearly demonstrated a difference between propranolol and diltiazem in patients with left ventricular dysfunction: propranolol substantially reduced the rate of cardiac death in these patients15 while diltiazem augmented the frequency of cardiac death in a similar group.10
The interaction of diltiazem and /-blockers within the MDPIT data base is potentially relevant because of shared negatively inotropic influences of these drugs. A diltiazem-associated increase in the frequency of late CHF was fully manifested in patients with EF less than 0.40 who were not taking /3-blockers ( Figure 4) . Thus, this increase did not require concomitant /3-blockade, which might have offered a preconditioning negatively inotropic action or inhibition of adrenergic compensation18 19 in patients with reduced EF. In fact, patients in each EF category who took /3-blockers had somewhat less frequent late CHF than corresponding patients not taking /3-blockers. A trend toward diltiazem enhancement of late CHF was evident in patients with EF less than 0.40 who took /3-blockers; /3-blockade did not eliminate this diltiazem influence.
The appearance of CHF during follow-up was clinically distinctive. In most cases the onset of CHF was judged to be a serious occurrence by managing physi- 
